Theragnostic imaging using radiolabeled antibodies and tyrosine kinase inhibitors.

Abstract excerpt

During the past decade, the efficacy of new molecular targeted drugs such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies has been proven worldwide, and molecular targeted therapies have become the mainstream in cancer therapy. However, clinical use of these new drugs presents unexpected adverse effects or poor therapeutic effects. Therefore, we require diagnostic tools to estimate the target...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibodies
• Share to Diagnostic Imaging
• Share to Mutation